Transcription of NEW ZEALAND DATA SHEET - Medsafe
{{id}} {{{paragraph}}}
Example: bachelor of science
NEW ZEALAND DATA SHEET - Medsafe
NEW ZEALAND DATA SHEETPage1of121 PRODUCT NAMECISPLATIN EBEWE 1 mg/mL Solution for injection2 QUALITATIVE AND QUANTITATIVE COMPOSITIONEach vial contains cisplatin 1 mg/mL10mg in 10mL, 50mg in 50mL and 100mg in 100mLExcipients with known effect: NoneFor the full list of excipients, see section PHARMACEUTICAL FORMS olution for colourless sterile aqueous CLINICAL indicationsCisplatin Ebewe is indicated as palliative therapy to be employed as follows:Metastatic Non-seminomatous Germ Cell Carcinoma:In established combination therapy with other approved chemotherapeutic agents in patientswith metastatic non-seminomatous germ cell tumours who have already received appropriatesurgical and/or radiotherapeutic Ovarian Tumours: cisplatin Ebewe, as a single agent, is indicated as secondary therapy in patients withmetastatic ovarian tumours refractory to standard chemotherapy who have not previouslyreceived cisplatin Ebewe and Refractory Carcinoma of the Bladder: cisplatin Ebewe, as a single agent, is indicated as secondary therapy in patients withadva
NEW ZEALAND DATA SHEET Page 1 of 12 1 PRODUCT NAME CISPLATIN EBEWE® 1 mg/mL Solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains cisplatin 1 mg/mL 10mg in 10mL, 50mg in 50mL and 100mg in 100mL
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: